{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:20:33Z","timestamp":1778134833574,"version":"3.51.4"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immunotherapy (IT) and radiotherapy (RT) have improved overall survival in patients with melanoma with brain metastasis (MBM). We examined the real\u2010world survival impact of IT and RT combination and timing strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>From the facility\u2010based National Cancer Database (NCDB) data set, 3008 cases of MBM were identified between 2011 and 2015. Six treatment cohorts were identified: stereotactic radiosurgery (SRS) + IT, SRS alone, whole brain radiotherapy (WBRT) + IT, WBRT alone, IT alone, and none. Concurrent therapy was defined as IT given within 28\u00a0days before or after RT; nonconcurrent defined as IT administered within 28\u201390\u00a0days of RT. The co\u2010primary outcomes were propensity score\u2010adjusted overall survival by treatment regimen and overall survival by RT and IT timing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median overall survival (mOS) was performed for each treatment category; SRS +IT 15.77\u00a0m; (95%CI 12.13\u201321.29), SRS alone (9.33\u00a0m; 95%CI: 8.0\u201311.3), IT alone (7.29\u00a0m; 95%CI: 5.35\u201312.91), WBRT +IT (4.89\u00a0m; 95%CI: 3.65\u20135.92), No RT or IT (3.29\u00a0m; 95%CI: 2.96\u20133.75), and WBRT alone (3.12\u00a0m; 95%CI 2.79\u20133.52). By propensity score matching, mOS for SRS +IT (15.5\u00a0m; 95%CI: 11.5\u201320.2) was greater than SRS alone (10.1\u00a0m; 95%CI: 8.4\u201311.8) (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.010), and median survival for WBRT +IT (4.6\u00a0m; 95%CI: 3.4\u20135.6) was greater than WBRT alone (2.9\u00a0m; 95%CI: 2.5\u20133.5) (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001). In the SRS +IT group, 24\u2010month landmark survival was 47% (95%CI; 42\u201352) for concurrent versus 37% (95%CI; 30\u201344) for nonconcurrent (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.40).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Those who received IT in addition to WBRT and SRS experienced longer survival compared to RT modalities alone, while those receiving concurrent SRS and IT trended toward improved survival versus nonconcurrent therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.3716","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T06:22:01Z","timestamp":1611382921000},"page":"1201-1211","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-1652","authenticated-orcid":false,"given":"Justin T.","family":"Moyers","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology Department of Internal Medicine Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0508-9521","authenticated-orcid":false,"given":"Esther G.","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4028-383X","authenticated-orcid":false,"given":"Jiahao","family":"Peng","sequence":"additional","affiliation":[{"name":"School of Public Health Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-9462","authenticated-orcid":false,"given":"Hsin Hsiang Clarence","family":"Tsai","sequence":"additional","affiliation":[{"name":"School of Medicine Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sufficool","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shavlik","sequence":"additional","affiliation":[{"name":"School of Public Health Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-6920","authenticated-orcid":false,"given":"Gayathri","family":"Nagaraj","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Internal Medicine Loma Linda University Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_9_3_1","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli M","year":"2014","journal-title":"In Vivo"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv381"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25634"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(78)90171-X"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26515"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70090-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30053-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30111-X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3171\/2012.5.JNS111929"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0588-y"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.140"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1573-4"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1283461"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-03020-y"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.08.025"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07213-1"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200819"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3032"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.315"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0282-x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.009"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1507669"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2019.00437"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.03.011"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30825-X"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016328"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00204"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9501"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2795-7"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30138"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.004"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000395"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7003"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.06.017"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.10.006"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0067"},{"key":"e_1_2_9_47_1","unstructured":"The Combination of Anti\u2010PD\u20101 With Radiotherapy in Previously Untreated Metastatic Melanoma https:\/\/ClinicalTrials.gov\/show\/NCT04017897."},{"key":"e_1_2_9_48_1","unstructured":"Pilot Study of the Safety\/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma https:\/\/ClinicalTrials.gov\/show\/NCT02659540."},{"key":"e_1_2_9_49_1","unstructured":"Radiation and Combination Immunotherapy for Melanoma https:\/\/ClinicalTrials.gov\/show\/NCT03850691."},{"key":"e_1_2_9_50_1","unstructured":"Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma https:\/\/ClinicalTrials.gov\/show\/NCT02406183."},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.062"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6905"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001312"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.08.055"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T11:37:41Z","timestamp":1717069061000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/cam4.3716"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3716","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"2020-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}